[Experimental justification of pathogenetically directed glaucoma therapy].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D004353:Drug Evaluation, Preclinical; D005901:Glaucoma / Q000188:drug therapy* / Q000209:etiology; D007429:Intraocular Pressure / Q000187:drug effects; D008094:Lithium / Q000627:therapeutic use; D011817:Rabbits; D013565:Sympatholytics
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D013565:Sympatholytics; D008094:Lithium
Eksperimental'noe obosnovanie patogeneticheski napravlennoĭ terapii glaukomy.